Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and ...

Investing.com — Kura Oncology, Inc. (NASDAQ: KURA )，一家市值5.75亿美元的临床阶段生物制药公司，宣布其关于KO-2806的临床前数据摘要已被美国癌症研究协会 (AACR)年会接受进行口头报告。根据 InvestingPro 分析，该公司在当前水平上似乎被低估，分析师设定的目标价格在每股10美元至40美元之间。该演讲计划于2025年4月28日进行 ...

After hours: March 25 at 7:31:01 PM EDT Loading Chart for KURA ...

tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the ...

KO-2806 and tipifarnib; the expected timing and presentation of results and data from clinical trials; and the anticipated timing of submission of an NDA for ziftomenib. Factors that may cause ...

Such forward-looking statements include statements regarding, among other things, the potential of FTIs to augment the antitumor activities of targeted therapies and to overcome resistance; the ...

Such forward-looking statements include statements regarding, among other things, the potential of FTIs to augment the antitumor activities of targeted therapies and to overcome resistance; the ...

Additionally, Kura is conducting a Phase 1/2 trial of tipifarnib, another farnesyl transferase inhibitor, in combination with alpelisib for PIK3CA-dependent head and neck squamous cell carcinoma ...